Over 10 million Americans have osteoporosis, and is the predominant cause of fractures in the elderly. Treatment of fractures in the setting of osteoporosis is complicated by a suboptimal bone regenerative response due to a decline in the number of osteoblasts, their function, and survival. Consequently, an osteogenic therapeutic to prevent and treat fractures in patients with osteoporosis is needed. Nel-like molecule-1 (NELL-1), a novel osteoinductive growth factor, has been shown to promote bone regeneration. In this study, we aim to demonstrate the capacity of recombinant NELL-1 to prevent ovariectomy (OVX)-induced osteoporosis in a senile rat model. Ten-month-old female Sprague-Dawley rats underwent either sham surgery or OVX. Subsequently, 50 μL of 600 μg/mL NELL-1 lyophilized onto a 0–50-μm tricalcium phosphate (TCP) carrier was injected into the femoral bone marrow cavity while phosphate-buffered saline (PBS) control was injected into the contralateral femur. Our microcomputed tomography results showed that OVX+PBS/TCP control femurs showed a continuous decrease in the bone volume (BV) and bone mineral density (BMD) from 2 to 8 weeks post-OVX. In contrast, OVX+NELL-1/TCP femurs showed resistance to OVX-induced bone resorption showing BV and BMD levels similar to that of SHAM femurs at 8 weeks post-OVX. Histology showed increased endosteal-woven bone, as well as decreased adipocytes in the bone marrow of NELL-1-treated femurs compared to control. NELL-1-treated femurs also showed increased immunostaining for bone differentiation markers osteopontin and osteocalcin. These findings were validated in vitro, in which addition of NELL-1 in OVX bone marrow stem cells resulted in increased osteogenic differentiation. Thus, NELL-1 effectively enhances in situ osteogenesis in the bone marrow, making it potentially useful in the prevention and treatment of osteoporotic fractures.
Get full access to this article
View all access options for this article.
References
1.
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis: Washington, DC, 2010.
2.
U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
3.
BurgeR., Dawson-HughesB., SolomonD.H., WongJ.B., KingA., TostesonA.Incidence and economic burden of osteoporotic fractures in the United States, 2005–2025. J Bone Miner Res, 22:465. 2007.
4.
PostT.M., CremersS.C., KerbuschT., DanhofM.Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet, 49:89. 2010.
5.
DominguezL.J., Di BellaG., BelvedereM., BarbagalloM.Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology, 12:397. 2011.
6.
KahnA., GibbonsR., PerkinsS., GazitD.Age-related bone loss. A hypothesis and initial assessment in mice. Clin Orthop Relat Res, 313:69. 1995.
7.
MuschlerG.F., NittoH., BoehmC.A., EasleyK.A.Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res, 19:117. 2001.
8.
GimbleJ.M., ZvonicS., FloydZ.E., KassemM., NuttallM.E.Playing with bone and fat. J Cell Biochem, 98:251. 2006.
9.
KhanS.N., LaneJ.M.The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther, 4:741. 2004.
10.
VahleJ.L., SatoM., LongG.G., YoungJ.K., FrancisP.C., EngelhardtJ.A.et al.Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol, 30:312. 2002.
11.
TashjianA.H.Jr., GagelR.F.Teriparatide [human PTH(1–34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res, 21:354. 2006.
12.
SewerynekE., StussM.Bisphosphonates and the risk of atrial fibrillation. Endokrynol Pol, 62:93. 2011.
13.
BoraiahS., PaulO., HawkesD., WickhamM., LorichD.G.Complications of recombinant human BMP-2 for treating complex tibial plateau fractures: a preliminary report. Clin Orthop Relat Res, 467:3257. 2009.
14.
CarrageeE.J., HurwitzE.L., WeinerB.K.A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J, 11:471. 2011.
15.
SciadiniM.F., JohnsonK.D.Evaluation of recombinant human bone morphogenetic protein-2 as a bone-graft substitute in a canine segmental defect model. J Orthop Res, 18:289. 2000.
16.
ZaraJ.N., SiuR.K., ZhangX., ShenJ., NgoR., LeeM.et al.High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng Part A, 17:1389. 2011.
17.
TingK., VastardisH., MullikenJ.B., SooC., TieuA., DoH.et al.Human Nell-1 expressed in unilateral coronal synostosis. J Bone Miner Res, 14:80. 1999.
18.
DesaiJ., ShannonM.E., JohnsonM.D., RuffD.W., HughesL.A., KerleyM.K.et al.Nell1-deficient mice have reduced expression of extracellular matrix proteins causing cranial and vertebral defects. Hum Mol Genet, 15:1329. 2006.
19.
SiuR.K., LuS.S., LiW., WhangJ., McNeillG., ZhangX.et al.Nell-1 protein promotes bone formation in a sheep spinal fusion model. Tissue Eng Part A, 17:1123. 2011.
JeeW.S., YaoW.Animal models of bone diseases. Introduction. J Musculoskelet Neuronal Interact, 1:183. 2001.
22.
HeneweerM., HoutmanR., PoortmanJ., GrootM., MaliepaardC., PeijnenburgA.Estrogenic effects in the immature rat uterus after dietary exposure to ethinylestradiol and zearalenone using a systems biology approach. Toxicol Sci, 99:303. 2007.
23.
PapaconstantinouA.D., UmbreitT.H., FisherB.R., GoeringP.L., LappasN.T., BrownK.M.Bisphenol A-induced increase in uterine weight and alterations in uterine morphology in ovariectomized B6C3F1 mice: role of the estrogen receptor. Toxicol Sci, 56:332. 2000.
24.
LiW., LeeM., WhangJ., SiuR.K., ZhangX., LiuC.et al.Delivery of lyophilized Nell-1 in a rat spinal fusion model. Tissue Eng Part A, 16:2861. 2010.
25.
ParfittA.M., DreznerM.K., GlorieuxF.H., KanisJ.A., MallucheH., MeunierP.J.et al.Bone histomorphometry: standardization of nomenclature, symbols, units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res, 2:595. 1987.
26.
JeeW.S., YaoW.Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact, 1:193. 2001.
27.
ThompsonD.D., SimmonsH.A., PirieC.M., KeH.Z.FDA Guidelines and animal models for osteoporosis. Bone, 17:125S. 1995.
28.
JamesA.W., LeuchtP., LeviB., CarreA.L., XuY., HelmsJ.A.et al.Sonic Hedgehog influences the balance of osteogenesis and adipogenesis in mouse adipose-derived stromal cells. Tissue Eng Part A, 16:2605. 2010.
29.
JamesA.W., PangS., AskarinamA., CorselliM., ZaraJ.N., GoyalR.et al.Additive effects of sonic hedgehog and nell-1 signaling in osteogenic versus adipogenic differentiation of human adipose-derived stromal cells. Stem Cells Dev, 21:2170. 2012.
30.
ZhangX., PeaultB., ChenW., LiW., CorselliM., JamesA.W.et al.The Nell-1 growth factor stimulates bone formation by purified human perivascular cells. Tissue Eng Part A, 17:2497. 2011.
31.
ChenF., WalderB., JamesA.W., SooferD.E., SooC., TingK.et al.NELL-1-dependent mineralisation of Saos-2 human osteosarcoma cells is mediated via c-Jun N-terminal kinase pathway activation. Int Orthop, 36:2181. 2012.
LeviB., JamesA.W., GlotzbachJ.P., WanD.C., CommonsG.W., LongakerM.T.Depot-specific variation in the osteogenic and adipogenic potential of human adipose-derived stromal cells. Plast Reconstr Surg, 126:822. 2010.
35.
RuthE.B.Bone studies. II. An experimental study of the Haversian-type vascular channels. Am J Anat, 93:429. 1953.
36.
de WinterF.R., SteendijkR.The effect of a low-calcium diet in lactating rats; observations on the rapid development and repair of osteoporosis. Calcif Tissue Res, 17:303. 1975.
37.
LiX.J., JeeW.S.S., KeH.Z., MoriS., AkamineT.Age related changes of cancellous and cortical bone histomorphometry in female Sprague-Dawley rats. Cells Mater (Suppl), 1:25. 1992.
38.
SchapiraD., Laton-MillerR., BarzilaiD., SilbermannM.The rat as a model for studies of the aging skeleton. Cells Mater (Suppl), 1:181. 1992.
39.
StegerR.W., HuangH.H., ChamberlainD.S., MeitesJ.Changes in control of gonadotropin secretion in the transition period between regular cycles and constant estrus in aging female rats. Biol Reprod, 22:595. 1980.
40.
MillerB.H., GoreA.C.N-Methyl-D-aspartate receptor subunit expression in GnRH neurons changes during reproductive senescence in the female rat. Endocrinology, 143:3568. 2002.
41.
TruongT., ZhangX., PathmanathanD., SooC., TingK.Craniosynostosis-associated gene nell-1 is regulated by runx2. J Bone Miner Res, 22:7. 2007.
42.
BokuiN., OtaniT., IgarashiK., KakuJ., OdaM., NagaokaT.et al.Involvement of MAPK signaling molecules and Runx2 in the NELL1-induced osteoblastic differentiation. FEBS Lett, 582:365. 2008.
43.
ZhangX., TingK., BessetteC.M., CuliatC.T., SungS.J., LeeH.et al.Nell-1, a key functional mediator of Runx2, partially rescues calvarial defects in Runx2(+/-) mice. J Bone Miner Res, 26:777. 2011.
44.
EgermannM., HeilP., TamiA., ItoK., JanickiP., Von RechenbergB.et al.Influence of defective bone marrow osteogenesis on fracture repair in an experimental model of senile osteoporosis. J Orthop Res, 28:798. 2010.
45.
XiaoY., FuH., PrasadamI., YangY.C., HollingerJ.O.Gene expression profiling of bone marrow stromal cells from juvenile, adult, aged and osteoporotic rats: with an emphasis on osteoporosis. Bone, 40:700. 2007.
46.
ChenT.L.Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone, 35:83. 2004.
47.
LiD.J., GeD.X., WuW.C., WuJ., LiL.[Osteogenic potential of bone marrow mesenchymal stem cells from ovariectomied osteoporotic rat]Sichuan Da Xue Xue Bao Yi Xue Ban, 36:318. 2005.
48.
LeeM., LiW., SiuR.K., WhangJ., ZhangX., SooC.et al.Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials, 30:6094. 2009.
49.
LeeM., SiuR.K., TingK., WuB.M.Effect of Nell-1 delivery on chondrocyte proliferation and cartilaginous extracellular matrix deposition. Tissue Eng Part A, 16:1791. 2010.
BraultV., MooreR., KutschS., IshibashiM., RowitchD.H., McMahonA.P.et al.Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development, 128:1253. 2001.
52.
RossS.E., HematiN., LongoK.A., BennettC.N., LucasP.C., EricksonR.L.et al.Inhibition of adipogenesis by Wnt signaling. Science, 289:950. 2000.
53.
ZhouS., EidK., GlowackiJ.Cooperation between TGF-beta and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res, 19:463. 2004.
KarasikD., HsuY.H., ZhouY., CupplesL.A., KielD.P., DemissieS.Genome-wide pleiotropy of osteoporosis-related phenotypes: the Framingham Study. J Bone Miner Res, 25:1555. 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
